Sitagliptin | hsa00230 | Purine metabolism | 4.48E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
Sitagliptin | hsa00270 | Cysteine and methionine metabolism | 1.92E-02 | 2 | Q96RQ9, P40926 | IL4I1, MDH2 | More | |
Sitagliptin | hsa00830 | Retinol metabolism | 3.19E-02 | 1 | P00325 | ADH1B | More | |
Sitagliptin | hsa01522 | Endocrine resistance | 6.51E-03 | 3 | Q08828, P51828, P31751 | ADCY1, ADCY7, AKT2 | More | |
Sitagliptin | hsa04010 | MAPK signaling pathway | 4.76E-02 | 5 | Q15283, P21860, Q12933, P01584, O14944 | RASA2, ERBB3, TRAF2, IL1B, EREG | More | |
Sitagliptin | hsa04015 | Rap1 signaling pathway | 3.69E-04 | 5 | P15498, Q08828, P51828, P31751, P0DP23 | VAV1, ADCY1, ADCY7, AKT2, CALM1 | More | |
Sitagliptin | hsa04020 | Calcium signaling pathway | 1.75E-03 | 6 | Q96DU7, Q08828, Q13557, P21860, P0DP23, P51828 | ITPKC, ADCY1, CAMK2D, ERBB3, CALM1, ADCY7 | More | |
Sitagliptin | hsa04022 | cGMP-PKG signaling pathway | 2.66E-03 | 4 | P31751, Q08828, P51828, P0DP23 | AKT2, ADCY1, ADCY7, CALM1 | More | |
Sitagliptin | hsa04024 | cAMP signaling pathway | 6.94E-05 | 5 | Q08828, P51828, P31751, P0DP23, P15498 | ADCY1, ADCY7, AKT2, CALM1, VAV1 | More | |
Sitagliptin | hsa04062 | Chemokine signaling pathway | 7.23E-03 | 4 | P15498, Q08828, P51828, P31751 | VAV1, ADCY1, ADCY7, AKT2 | More | |
Sitagliptin | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 6 | Q9H228, P01375, Q13362, Q9BX95, P10415, Q9UQC2 | EDG8, TNF, PPP2R5C, SGPP1, BCL2, GAB2 | More | |
Sitagliptin | hsa04072 | Phospholipase D signaling pathway | 1.67E-02 | 3 | P31751, Q08828, P51828 | AKT2, ADCY1, ADCY7 | More | |
Sitagliptin | hsa04114 | Oocyte meiosis | 1.67E-02 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | |
Sitagliptin | hsa04211 | Longevity regulating pathway | 6.51E-03 | 3 | P31751, Q08828, P51828 | AKT2, ADCY1, ADCY7 | More | |
Sitagliptin | hsa04213 | Longevity regulating pathway - multiple species | 2.91E-03 | 3 | P31751, Q08828, P51828 | AKT2, ADCY1, ADCY7 | More | |
Sitagliptin | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.17E-03 | 4 | Q08828, P51828, P31751, P0DP23 | ADCY1, ADCY7, AKT2, CALM1 | More | |
Sitagliptin | hsa04270 | Vascular smooth muscle contraction | 9.93E-03 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | |
Sitagliptin | hsa04340 | Hedgehog signaling pathway | 1.80E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | |
Sitagliptin | hsa04371 | Apelin signaling pathway | 1.09E-03 | 4 | P31751, Q08828, P51828, P0DP23 | AKT2, ADCY1, ADCY7, CALM1 | More | |
Sitagliptin | hsa04380 | Osteoclast differentiation | 6.51E-03 | 3 | Q9NQC7, P23458, P31751 | CYLD, JAK1, AKT2 | More | |
Sitagliptin | hsa04540 | Gap junction | 3.73E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
Sitagliptin | hsa04611 | Platelet activation | 5.11E-03 | 3 | P31751, Q08828, P51828 | AKT2, ADCY1, ADCY7 | More | |
Sitagliptin | hsa04625 | C-type lectin receptor signaling pathway | 3.91E-03 | 3 | Q9NQC7, P31751, P0DP23 | CYLD, AKT2, CALM1 | More | |
Sitagliptin | hsa04630 | JAK-STAT signaling pathway | 2.91E-03 | 3 | P31751, P23458, Q13651 | AKT2, JAK1, IL10RA | More | |
Sitagliptin | hsa04662 | B cell receptor signaling pathway | 2.41E-02 | 2 | P31751, P15498 | AKT2, VAV1 | More | |
Sitagliptin | hsa04664 | Fc epsilon RI signaling pathway | 2.41E-02 | 2 | P31751, P15498 | AKT2, VAV1 | More | |
Sitagliptin | hsa04668 | TNF signaling pathway | 1.26E-02 | 4 | Q12933, Q99941, P01584, O95429 | TRAF2, CREBL1, IL1B, BAG4 | More | |
Sitagliptin | hsa04713 | Circadian entrainment | 5.31E-04 | 5 | P0DP23, Q13557, Q02153, Q08828, P51828 | CALM1, CAMK2D, GUCY1B3, ADCY1, ADCY7 | More | |
Sitagliptin | hsa04720 | Long-term potentiation | 3.73E-02 | 2 | P0DP23, Q08828 | CALM1, ADCY1 | More | |
Sitagliptin | hsa04723 | Retrograde endocannabinoid signaling | 4.48E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
Sitagliptin | hsa04724 | Glutamatergic synapse | 3.73E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
Sitagliptin | hsa04725 | Cholinergic synapse | 5.11E-03 | 3 | Q08828, P51828, P31751 | ADCY1, ADCY7, AKT2 | More | |
Sitagliptin | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.11E-04 | 5 | P01584, Q08828, P51828, Q13557, P0DP23 | IL1B, ADCY1, ADCY7, CAMK2D, CALM1 | More | |
Sitagliptin | hsa04910 | Insulin signaling pathway | 3.04E-02 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | |
Sitagliptin | hsa04911 | Insulin secretion | 1.32E-03 | 4 | Q08828, P51828, Q99941, Q13557 | ADCY1, ADCY7, CREBL1, CAMK2D | More | |
Sitagliptin | hsa04912 | GnRH signaling pathway | 5.11E-03 | 3 | Q08828, P51828, P0DP23 | ADCY1, ADCY7, CALM1 | More | |
Sitagliptin | hsa04913 | Ovarian steroidogenesis | 1.85E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
Sitagliptin | hsa04914 | Progesterone-mediated oocyte maturation | 6.51E-03 | 3 | Q08828, P51828, P31751 | ADCY1, ADCY7, AKT2 | More | |
Sitagliptin | hsa04915 | Estrogen signaling pathway | 2.66E-03 | 4 | Q08828, P51828, P31751, P0DP23 | ADCY1, ADCY7, AKT2, CALM1 | More | |
Sitagliptin | hsa04916 | Melanogenesis | 1.41E-03 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | |
Sitagliptin | hsa04918 | Thyroid hormone synthesis | 4.48E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
Sitagliptin | hsa04921 | Oxytocin signaling pathway | 1.42E-02 | 3 | P0DP23, Q08828, P51828 | CALM1, ADCY1, ADCY7 | More | |
Sitagliptin | hsa04923 | Regulation of lipolysis in adipocytes | 2.69E-04 | 3 | Q08828, P51828, P31751 | ADCY1, ADCY7, AKT2 | More | |
Sitagliptin | hsa04924 | Renin secretion | 3.64E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | |
Sitagliptin | hsa04925 | Aldosterone synthesis and secretion | 3.91E-03 | 3 | Q08828, P51828, P0DP23 | ADCY1, ADCY7, CALM1 | More | |
Sitagliptin | hsa04926 | Relaxin signaling pathway | 8.11E-03 | 3 | P31751, Q08828, P51828 | AKT2, ADCY1, ADCY7 | More | |
Sitagliptin | hsa04927 | Cortisol synthesis and secretion | 1.85E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
Sitagliptin | hsa04932 | Non-alcoholic fatty liver disease | 4.44E-02 | 4 | Q12933, P01584, P12074, O15239 | TRAF2, IL1B, COX6A1, NDUFA1 | More | |
Sitagliptin | hsa04934 | Cushing syndrome | 5.31E-04 | 5 | Q99941, Q08828, P51828, O15169, Q13557 | CREBL1, ADCY1, ADCY7, AXIN1, CAMK2D | More | |
Sitagliptin | hsa04935 | Growth hormone synthesis, secretion and action | 6.51E-03 | 3 | Q08828, P51828, P31751 | ADCY1, ADCY7, AKT2 | More | |
Sitagliptin | hsa04970 | Salivary secretion | 9.02E-04 | 3 | Q08828, P51828, P0DP23 | ADCY1, ADCY7, CALM1 | More | |
Sitagliptin | hsa04971 | Gastric acid secretion | 1.41E-03 | 3 | Q08828, P51828, P0DP23 | ADCY1, ADCY7, CALM1 | More | |
Sitagliptin | hsa04972 | Pancreatic secretion | 2.41E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
Sitagliptin | hsa04976 | Bile secretion | 1.85E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
Sitagliptin | hsa05010 | Alzheimer disease | 1.23E-02 | 8 | Q92542, O15239, P05496, P12074, P01584, Q12933, O15169, P43686 | NCSTN, NDUFA1, ATP5G1, COX6A1, IL1B, TRAF2, AXIN1, PSMC4 | More | |
Sitagliptin | hsa05012 | Parkinson disease | 3.53E-02 | 6 | P62987, O15239, P12074, P05496, P43686, Q13557 | UBA52, NDUFA1, COX6A1, ATP5G1, PSMC4, CAMK2D | More | |
Sitagliptin | hsa05014 | Amyotrophic lateral sclerosis | 2.99E-02 | 7 | O15239, P12074, P05496, Q12933, P43686, P37198, P35658 | NDUFA1, COX6A1, ATP5G1, TRAF2, PSMC4, NUP62, NUP214 | More | |
Sitagliptin | hsa05020 | Prion disease | 2.99E-02 | 7 | P01584, P46531, O15239, P05496, P12074, P43686, Q99941 | IL1B, NOTCH1, NDUFA1, ATP5G1, COX6A1, PSMC4, CREBL1 | More | |
Sitagliptin | hsa05022 | Pathways of neurodegeneration - multiple diseases | 9.10E-03 | 9 | O15239, P12074, P05496, Q12933, O15169, P01584, Q13557, P62987, P43686 | NDUFA1, COX6A1, ATP5G1, TRAF2, AXIN1, IL1B, CAMK2D, UBA52, PSMC4 | More | |
Sitagliptin | hsa05032 | Morphine addiction | 2.41E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |
Sitagliptin | hsa05135 | Yersinia infection | 2.24E-02 | 3 | Q14161, P15498, P31751 | GIT2, VAV1, AKT2 | More | |
Sitagliptin | hsa05142 | Chagas disease | 4.48E-02 | 2 | Q08828, P31751 | ADCY1, AKT2 | More | |
Sitagliptin | hsa05144 | Malaria | 4.92E-02 | 4 | O60603, P01375, P35443, P26718 | TLR2, TNF, THBS4, KLRK1 | More | |
Sitagliptin | hsa05145 | Toxoplasmosis | 1.67E-02 | 3 | P23458, P31751, Q13651 | JAK1, AKT2, IL10RA | More | |
Sitagliptin | hsa05152 | Tuberculosis | 9.49E-03 | 4 | P0DP23, P23458, P31751, Q13651 | CALM1, JAK1, AKT2, IL10RA | More | |
Sitagliptin | hsa05163 | Human cytomegalovirus infection | 2.17E-04 | 6 | P31751, P0DP23, Q08828, P51828, P23458, Q13651 | AKT2, CALM1, ADCY1, ADCY7, JAK1, IL10RA | More | |
Sitagliptin | hsa05164 | Influenza A | 3.67E-02 | 3 | P31751, P23458, Q9UBU9 | AKT2, JAK1, NXF1 | More | |
Sitagliptin | hsa05166 | Human T-cell leukemia virus 1 infection | 3.02E-02 | 4 | P23458, Q08828, P51828, P31751 | JAK1, ADCY1, ADCY7, AKT2 | More | |
Sitagliptin | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 2.24E-02 | 3 | P31751, P23458, P0DP23 | AKT2, JAK1, CALM1 | More | |
Sitagliptin | hsa05168 | Herpes simplex virus 1 infection | 2.09E-02 | 4 | Q9UBU9, P23458, P31751, Q6NUN9 | NXF1, JAK1, AKT2, ZNF746 | More | |
Sitagliptin | hsa05200 | Pathways in cancer | 1.65E-02 | 5 | P23458, P31751, Q08828, P51828, P0DP23 | JAK1, AKT2, ADCY1, ADCY7, CALM1 | More | |
Sitagliptin | hsa05212 | Pancreatic cancer | 2.41E-02 | 2 | P31751, P23458 | AKT2, JAK1 | More | |
Sitagliptin | hsa05214 | Glioma | 1.85E-02 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | |
Sitagliptin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.48E-02 | 2 | P31751, P23458 | AKT2, JAK1 | More | |
Sitagliptin | hsa05321 | Inflammatory bowel disease | 4.92E-02 | 4 | O60603, P01375, Q14765, Q9UL17 | TLR2, TNF, STAT4, TBX21 | More | |
Sitagliptin | hsa05332 | Graft-versus-host disease | 1.80E-02 | 4 | P10747, P01375, P26715, Q13241 | CD28, TNF, KLRC1, KLRD1 | More | |
Sitagliptin | hsa05414 | Dilated cardiomyopathy | 4.48E-02 | 2 | Q08828, P51828 | ADCY1, ADCY7 | More | |